Monopar Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing proprietary therapeutics for cancer patients. It also focuses on building a drug development pipeline through the licensing, and acquisition of therapeutics in late preclinical and clinical development stages. The company was founded by Chandler Drew Robinson, Christopher M. Starr and Andrew P. Mazar in December 2014 and is headquartered in Wilmette, IL.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
22
Frequently Asked Questions
Market cap, also known as market capitalization, is the total market value of a company. It's calculated by multiplying the current market price by the total number of shares outstanding. Monopar Therapeutics Inc market cap is $467.6M.
52 week high is the highest price of a stock in the past 52 weeks, or one year. Monopar Therapeutics Inc 52 week high is $124.82 as of November 21, 2026.
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Monopar Therapeutics Inc 52 week low is $50.07 as of November 21, 2026.
Monopar Therapeutics Inc stock price today is $69.00.
Monopar Therapeutics Inc stock price yesterday was $70.29.
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It's calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company's Market Cap by the Net Profit. Monopar Therapeutics Inc's P/E ratio is -26.75.
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It's calculated by dividing a company's market capitalization by its book value. Monopar Therapeutics Inc P/B ratio is 3.6722.
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It's calculated by averaging the closing stock price over the previous 50 trading days. Monopar Therapeutics Inc 50-day moving average is $78.36.